
    
      2 part study description:

      • an initial Phase 1a single ascending dose (SAD) phase to identify a safe dose of OPT101.

      Dose escalation will be by a factor of 2.6: 0.16, 0.42, 1.1, 2.8 and 7.3mg/kg.

      • a Phase 1b multiple ascending dose (MAD) phase to measure safety and clinical effects of
      the highest and next to highest dose of OPT101 that are found to be safe in Phase 1a.
    
  